Irvine, California-based Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has acquired iRenix Medical, Inc., a privately held clinical-stage ophthalmic biopharmaceutical company, in a deal structured to bring IRX-101, an investigational ocular antiseptic, into Tarsus's US ophthalmology pipeline. The acquisition signals Tarsus's strategic pivot beyond its commercially established Demodex blepharitis franchise into the retinal disease space, where more than 11 million intravitreal injections are performed annually in the US.
The deal carries an upfront consideration of approximately USD 75 million, split equally between USD 37.5 million in cash and USD 37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to USD 490 million, bringing the total potential deal value to approximately USD 565 million. No royalty terms or individual milestone tranches were disclosed. Geographic scope was not specified, though the acquisition is structured as a full company purchase of iRenix Medical with no disclosed carve-outs.
IRX-101 is a stable aqueous chlorine dioxide solution formulated for topical ocular surface application as a pre-procedural antiseptic for intravitreal injections. It is designed to replace 5% povidone-iodine (Betadine), which has served as the standard of care for ocular surface sterilization prior to intravitreal procedures for more than four decades. IRX-101's mechanism — broad-spectrum antimicrobial activity via chlorine dioxide on the ocular surface — does not involve intravitreal delivery and is applied topically before injection. The drug successfully completed the Phase 2b/3 RELIEF trial, and based on data from that study and FDA feedback Tarsus plans to initiate a confirmatory Phase III safety and tolerability study in H1 2027.